Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2006

View Archived Issues

Wyeth and Karo Bio extend atherosclerosis collaboration

Savient completes sale of Rosemont Pharmaceuticals

Predix expands agreement with Cystic Fibrosis Foundation Therapeutics

AVR-118 accelerates wound healing in pig study

Successful phase I data on 131-I-TM-601 in glioma patients reported

Galapagos and AstraZeneca form drug discovery collaboration

FemmePharma opens IND for topical treatment for breast pain

IMP-321 begins phase I chemoimmunotherapy trial in metastatic breast cancer

European orphan drug designation for SLIT Amikacin

NovaDel begins bioequivalence trial for proprietary zolpidem oral spray

Phase III study of pixantrone in NHL cleared to continue

EVT-101 completes phase I testing

MacuSight's ophthalmic formulation of sirolimus cleared for phase I studies

IDEA-033 yields pain reduction in patients with osteoarthritis of the knee

Pancreatic cancer studies of glufosfamide complete enrollment

Taisho and Lilly terminate TS-021 license agreement

PXD-101 studied with azacitidine for advanced hematologic malignancies

Velcade granted priority review for relapsed mantle cell lymphoma

Elan updates quarterly progress

Clinical efficacy of bevacizumab-erlotinib HCl combination in NSCLC

First evidence of analgesic effects of CHF-3381 in human pain model

New insights into HMG-CoA synthase structure reported

Recent patents cover therapeutic agents for neurological disorders

Novel anti-HCV agents reported in recent Genelabs patent

New chemokine receptor ligands for HIV reported in recent GSK patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...